Familial Hypercholesterolemia - Heterozygous research hub

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

This study is testing a new medicine, inclisiran, for children aged 6-11 with a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to see how well inclisiran lowers 'bad' cholesterol and if it's safe for them.